Mostly Cloudy80° WeatherMostly Cloudy80° Weather
feeling fine

Consider the pros, cons of new weight-loss drugs Belviq and Qsymia

Weight-loss drugs have so far been a complete bust. But they may be verging on a comeback, now that the Food and Drug Administration has approved two new prescription diet pills for the first time in more than a decade. ¶ Both weight-loss medications failed to get federal approval in 2010 because of safety concerns, including heart risks and birth defects. After the drug companies submitted additional safety data, however, the agency okayed the applications. ¶ Critics argue that weight-loss drugs don't have enough benefits to justify the risk. But resources aimed at improving diet and increasing physical activity have not been helping the nearly one in three Americans dealing with extreme weight gain. ¶ The drugs are meant for overweight and obese adults with a body mass index (BMI) greater than 30, or for those who have a weight-related condition, such as high blood pressure, elevated cholesterol or Type 2 diabetes, and a BMI over 27. Pregnant women shouldn't touch these drugs. And "they should never be taken for cosmetic purposes," said Dr. Donna Ryan, professor emeritus at Pennington Biomedical Research Center in Louisiana and a consultant to drug companies. ¶ But do they work? Are they safe? Here's the skinny:

Belviq

How it works: Belviq, or lorcaserin, activates a serotonin receptor in the brain that may help a person eat less and feel full after eating smaller amounts of food. In clinical trials, patients on average lost just 5 percent of body weight after taking the drug for a year along with eating less and exercising more.

Concerns: The drug could potentially damage heart valves. Fenfluramine, a similar serotonin-based weight-loss drug, was taken off the market in 1997 due to the same heart concerns. Belviq shows "an increased incidence of adverse reactions related to cognition and mood," according to the FDA. Still unknown: the long-term risk of heart attack and stroke, and the safety and efficacy when used with other diet medications. The most common side effects are headache, dizziness, fatigue, nausea, dry mouth and constipation.

Qsymia

How it works: Qsymia is a combination of two FDA-approved drugs, phentermine and an extended-release form of topiramate. Phentermine increases levels of norepinephrine, a neurotransmitter in the part of the brain that controls appetite. This reduces hunger and increases satiety. Topiramate, an anticonvulsant used to prevent migraine headaches, is thought to affect another neurotransmitter. But it's not known how it reduces food intake, Ryan said. Approximately 62 percent of patients who took the recommended dose for a year, and dieted and exercised, lost at least 5 percent of their body weight, according to two trials.

Concerns: Birth defects are a biggie: The drug can increase the risk of cleft lip and palate. Topiramate may cause suicidal thoughts or actions. Qsymia can slow down brain function and increase heart rate; the drug's effect on patients at high risk for heart attack and stroke isn't known. Qsymia has not been approved by European regulators.

Consider the pros, cons of new weight-loss drugs Belviq and Qsymia 12/28/12 [Last modified: Friday, December 28, 2012 3:30am]

Copyright: For copyright information, please check with the distributor of this item, McClatchyTribune.
    

Join the discussion: Click to view comments, add yours

Loading...